JPMORGAN JESSICA FYE Analyst dropped the company goal to modern (Mrna) up to $ 33 from $ 40 and holds a rating of too little weight on stocks, primarily due to more conservative assessment of RSV flu. The company now moderates the 2025 RSV sales of about $ 148 million, compared to a previous estimate of around $ 210 million, and for FY25 now it modeled a total revenue of $ 2.1 billion, compared to consensus of $ 2.2 billion, and just above 2B USD Sidionce Sidionce, analyst says to investors.
Published first on Thefly -Real -time short source, on the market that moves in breaking the financial news. Try now >>
Look at the hot stock of insiders on the Tipranks >>
Read more about Mrna:
Questions or comments about the article? Write at editor@tipranks.com
